Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.
Rachel K. Anderson, PharmD, CSP
Advertisement
Articles by Rachel K. Anderson, PharmD, CSP
PARP inhibitors in particular have changed the therapeutic landscape for EOC.
Numerous clinical trials are investigating the next generation of PARPi.
Trends in treatment development involve more targeted, safe, and efficacious therapies.
Rachel K. Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.
The disease can often be detected and managed early before a patient experiences signs or symptoms.
Biosimilars could save consumers more than $100 billion in the coming years.
Advertisement
Latest Updated Articles
Oncology Biosimilars Enter an Era of ExpansionPublished: April 13th 2022 | Updated:
Current Treatment Modalities, Available Therapeutics for Prostate Cancer See GrowthPublished: August 26th 2022 | Updated:
Clinical Insights Into Advancements in Epithelial Ovarian Cancer TreatmentPublished: February 10th 2023 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
